COMP <GO>
CUE vs PDSB // FORWARD P/E MULTIPLE
Cue Biopharma Inc. (NASDAQ) VS. PDS Biotechnology Corporation (NASDAQ) • 15-METRIC TALLY: CUE 3
— PDSB 1
■ METRIC PARITY
LAST: $19.42 (-6.95%) • MKT CAP: $151.6M
forward-pe
—
LAST: $1.37 (-4.86%) • MKT CAP: $151.2M
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CUE VS. PDSB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CUE | PDSB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -14.03% | -17.05% | +3.02 | CUE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | CUE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 60.0 | -13.30 | PDSB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $151.6M | $151.2M | $400.5K | CUE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CUE REV | PDSB REV | CUE GROSS % | PDSB GROSS % | CUE FCF | PDSB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $27.5M | $88.3M | — | — | -$21.9M | -$27.8M |
| FY 2024 | $9.3M | $101.7M | — | — | -$36.4M | -$35.1M |
| FY 2023 | $5.5M | $120.5M | — | — | -$40.0M | -$33.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CUE // BETA —
PDSB // BETA —